Trial Profile
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2021
Price :
$35
*
At a glance
- Drugs IC 51 (Primary) ; Hepatitis A vaccine inactivated; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Japanese encephalitis
- Focus Adverse reactions; Registrational
- Sponsors Intercell
- 24 Apr 2017 Results published in the Pediatric Infectious Disease Journal
- 19 Apr 2017 Results assessing immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine in subgroup of patients (n=496), published in the Pediatric Infectious Disease Journal
- 21 Jun 2013 Results from this trial were used to support new US recommendations for use of the vaccine in children, according to a Valneva media release.